Business Context and Reporting Period
Relmada Therapeutics, Inc. (RLMD) filed a Form 8-K on July 7, 2025, reporting the termination of a material definitive agreement. The Company, incorporated in Nevada and headquartered in Coral Gables, FL, is a biopharmaceutical entity focused on developing novel therapeutics.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial data disclosed relates to the terminated agreement:
- Upfront License Fee: $180,000 (paid in January 2018).
- Recurring Payments: $45,000 per quarter paid to the Licensor.
- Termination Timeline: Material obligations cease 90 days after the July 7, 2025 notice.
Material Changes
The primary material change is the formal termination of the License Agreement with Dr. Charles E. Inturrisi and Dr. Paolo Manfredi regarding esmethadone. This action ends the Company's participation in the previously announced esmethadone development program. Consequently, the obligation to pay the quarterly $45,000 fee will cease 90 days post-notice.
Outlook, Risks, and Management Commentary
Management has elected to discontinue the esmethadone development program. The filing indicates that no commercial sales, patent expirations, or invalidations had occurred prior to this voluntary termination. The cessation of the program eliminates future royalty obligations (tiered rates up to 2% on net sales) and sublicense payments (up to 20%) associated with this specific asset.
Investor Verification Checklist
- Verify the exact date the 90-day termination period concludes to confirm when the $45,000 quarterly payments stop.
- Review the Company's most recent 10-Q or 10-K to assess the impact of this termination on overall cash burn and liquidity.
- Confirm if the termination triggers any other contractual obligations or penalties not explicitly detailed in this 8-K.
- Assess the strategic rationale for abandoning the esmethadone program in the context of the Company's remaining pipeline.